Interventional device developer Boston Scientific of Natick, MA, and pharmaceutical company NitroMed of Bedford, MA, have extended the firms’ collaboration, licensing and commercialization agreement for the development of nitric-oxide-coated stents to complement Boston Scientific’s paclitaxel-coated stent.